Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma

If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2015
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Dove Medical Press
Abstract

BACKGROUND: Acceptable post-orchiectomy adjuvant therapy strategies for stage I seminoma patients include surveillance, para-aortic radiation therapy (RT), dog-leg RT, and a single cycle of carboplatin. The required follow-up recommendations were amended by the National Comprehensive Cancer Network (NCCN) in 2012. Given a cause-specific survival of nearly 100%, a closer analysis of the reimbursement for each treatment strategy is warranted. METHODS: NCCN guidelines were used to design treatment plans for each acceptable adjuvant treatment strategy. Follow-up charges were generated for 10 years based on 2012 (version 1.2012; unchanged in current version 1.2013) and 2011 NCCN (version 2.2011) surveillance recommendations. The 2012 Medicare reimbursement rates were used to calculate each treatment strategy and incremental cost-effectiveness ratios to compare the treatment options. RESULTS: Under the current NCCN follow-up recommendations, the total reimbursements generated over 10 years of surveillance, para-aortic RT, dog-leg RT, and carboplatin were $10,643, $11,678, $9,662, and $10,405, respectively. This is compared with the reimbursements as per the 2011 NCCN recommendations: $20,986, $11,517, $9,394, and 20,365respectively.Factoringtheratesofrelapseintoasalvagemodel,observationwasfoundtobemorecostlyandlesseffective(-1,831, $-7,318, $-7,010) in the adjuvant management of stage I seminoma patients. CONCLUSION: Based on incremental cost-effectiveness ratios, para-aortic RT, dog-leg RT, and carboplatin are cost-effective options for the treatment of stage I seminoma when compared with observation; however, surveillance could potentially spare as many as 80%-85% of men diagnosed with stage I seminoma from additional therapy after radical inguinal orchiectomy. Such cost and reimbursement analyses are becoming increasingly relevant, but are not meant to usurp sound clinical judgment. Further studies are required to validate these findings.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Cox, J. A., Gajjar, S. R., Lanni, T. B., & Swanson, T. A. (2015). Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma. Research and Reports in Urology, 7, 1–7. http://doi.org/10.2147/RRU.S74125
ISSN
2253-2447
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Research and Reports in Urology
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Final published version
Full Text Available at
This item is under embargo {{howLong}}